{
  "id": 14350363,
  "title": "PTC Therapeutics CLO Mark Boulding sells $12,337 in stock",
  "url": "https://urgent.news/2026/10/14/ptc-therapeutics-clo-mark-boulding-sells-12-337-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T02:31:15.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ptc-therapeutics-clo-mark-boulding-sells-12337-in-stock-93CH-4947899"
  },
  "original_language": "en",
  "account": "PTC Therapeutics' Chief Legal Officer Mark Boulding recently sold 192 shares of company stock on October 9, 2026. This sale, valued at $12,337, occurred concurrently with the purchase of 192 shares through stock options. The stock traded at $59.92, nearing its 52-week low. PTC Therapeutics is currently considered undervalued based on InvestingPro's analysis, appearing on their list of Most Undervalued stocks. Boulding now owns 105,272 shares of the company. His transactions were executed under a pre-approved Rule 10b5-1 trading plan.",
  "summary": null,
  "key_points": [
    "Chief Legal Officer Mark Boulding sold 192 shares of PTC Therapeutics on October 9, 2026.",
    "Sale valued at $12,337 occurred as shares traded at $59.92, near 52-week low.",
    "Boulding now owns 105,272 shares, following pre-approved Rule 10b5-1 trading plan."
  ],
  "editors_take": "The executive's automated transaction highlights a routine liquidity event rather than a shift in sentiment, as the sale occurred through a pre-approved plan while the stock neared its yearly low.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock",
        "url": "https://urgent.news/2026/10/14/ocular-therapeutix-clo-todd-anderman-sells-87-363-in-company-stock",
        "published": "2026-10-14T03:16:19.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}